-
1.发明申请公开(公告)号：US20180325860A1
公开(公告)日：2018-11-15
申请号：US15777141
申请日：2016-11-17
申请人： Kip M. CONNOR , Eiichi HASEGAWA , Bruce D. HAMMOCK , Kin Sing Stephen LEE , Massachusetts Eye and Ear Infirmary , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IPC分类号： A61K31/336 , A61K9/00 , A61P27/06
CPC分类号： A61K31/336 , A61K9/0019 , A61K9/0048 , A61K31/17 , A61K31/202 , A61K31/445 , A61K31/4468 , A61K2300/00 , A61P27/02 , A61P27/04 , A61P27/06
摘要： This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).
-
公开(公告)号：US10758511B2
公开(公告)日：2020-09-01
申请号：US15777141
申请日：2016-11-17
IPC分类号： A61K31/17 , A61K31/202 , A61K31/336 , A61K31/445 , A61K31/4468 , A61P27/02 , A61P27/04 , A61P27/06 , A61K9/00
摘要： This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).
-
公开(公告)号：US11426385B2
公开(公告)日：2022-08-30
申请号：US16641430
申请日：2018-08-14
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , United States as represented by the Department of Veterans Affairs
发明人： Bruce D. Hammock , Sung Hee Hwang , Ralph W. de Vere White , Chong-xian Pan , Hongyong Zhang , Paul Henderson , Ai-Hong Ma , Maike Zimmermann , Fuli Wang
IPC分类号： A61K31/415 , A61P35/00 , A61K33/243 , A61K31/7068 , A61K45/06
摘要： Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase (“COX”)-1, COX-2, and 5-lipoxygenase (“5-LOX”). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.
-
公开(公告)号：US10449182B2
公开(公告)日：2019-10-22
申请号：US14408280
申请日：2013-06-20
IPC分类号： A61K31/44 , A61K31/4439 , A61K31/17 , A61K31/192 , A61K31/277 , A61P35/02 , A61P35/00 , A61K31/4412 , A61K45/06 , A61K31/196 , A61K31/675 , A61K31/704 , A61K33/24
摘要： The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
-
公开(公告)号：US10322118B2
公开(公告)日：2019-06-18
申请号：US14982298
申请日：2015-12-29
IPC分类号： A61P11/00 , A61K9/00 , A61K31/17 , A61K31/09 , A61K31/445 , A61K31/192 , A61K31/198 , A61K31/085 , A61K31/415 , C12Q1/34 , A61K31/336 , A61K31/00
摘要： The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
-
公开(公告)号：US09850207B2
公开(公告)日：2017-12-26
申请号：US14375704
申请日：2013-02-01
发明人： Bruce D. Hammock , Kin Sing Lee , Bora Inceoglu , Karen Wagner
IPC分类号： C07D211/58 , C07D211/96 , A61K31/4468
CPC分类号： C07D211/96 , A61K31/4468 , C07D211/58
摘要： Provided are methods for treating, reducing, alleviating, and/or inhibiting neuropathic pain by orally, intravenously or intrathecally administering an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”), to a patient in need thereof. The neuropathic pain treated is selected from the group consisting of post-herpetic neuralgia, trigeminal neuralgia, focal peripheral nerve injury, and anesthesia dolorosa, central pain due to stroke or mass lesion, spinal cord injury, or multiple sclerosis, and peripheral neuropathy due to diabetes, HIV, or chemotherapy.
-
公开(公告)号：US11723929B2
公开(公告)日：2023-08-15
申请号：US16621649
申请日：2018-06-11
IPC分类号： C12N5/074 , A61K35/34 , A61K31/453 , A61K45/06 , A61L31/16
CPC分类号： A61K35/34 , A61K31/453 , A61K45/06 , A61L31/16 , C12Y303/0201
摘要： Provided are methods for improving the efficacy and success of cell-based therapies by administration of stem cells which have been preconditioned with an inhibitor of soluble epoxide hydrolase (sEHI), as well as kits, stents and patches for administering sEHI-preconditioned stem cells, as sole active agent or in combination with an agent that increases the production and or levels of EETs.
-
公开(公告)号：US10383835B2
公开(公告)日：2019-08-20
申请号：US14384910
申请日：2013-03-05
IPC分类号： A61K31/196 , A61K31/17 , A61K45/06 , A61K31/167 , A61K31/192 , A61K31/405 , A61K31/415 , A61K31/451 , A61K31/513 , A61K31/5415 , A61K31/603 , A61K31/197 , A61K31/4152
摘要： The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.
-
公开(公告)号：US20160206605A1
公开(公告)日：2016-07-21
申请号：US14982298
申请日：2015-12-29
IPC分类号： A61K31/445 , A61K31/192 , A61K31/198 , A61K31/336 , A61K31/17 , A61K31/415 , C12Q1/34 , A61K9/00 , A61K31/085
CPC分类号： A61K31/445 , A61K9/0043 , A61K9/0073 , A61K31/00 , A61K31/085 , A61K31/09 , A61K31/17 , A61K31/192 , A61K31/198 , A61K31/336 , A61K31/415 , A61P11/00 , C12Q1/34 , G01N2500/02
摘要： The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
摘要翻译： 本发明提供了用于鉴定铜绿假单胞菌CFTR抑制因子的抑制剂的筛选测定，以及用于改善或治疗呼吸系统疾病如囊性纤维化或其继发感染的组合物和方法。
-
公开(公告)号：US20150045389A1
公开(公告)日：2015-02-12
申请号：US14386850
申请日：2013-04-09
IPC分类号： C07D231/12 , C07D211/96 , C12Q1/34 , C07C59/135 , C07C275/28 , C07C275/30 , C07D211/58 , C07C229/08
CPC分类号： C07D231/12 , A61K9/0073 , A61K31/202 , A61K31/336 , C07C59/135 , C07C229/08 , C07C275/28 , C07C275/30 , C07D211/58 , C07D211/96 , C12Q1/34 , G01N33/6893 , G01N2500/02 , G01N2800/382
摘要： The present invention is a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compounds identified by the screening assay for use in compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
摘要翻译： 本发明是用于鉴定铜绿假单胞菌CFTR抑制因子的抑制剂的筛选试验以及通过用于改善或治疗呼吸系统疾病如囊性纤维化或继发感染的组合物和方法中的筛选测定法鉴定的化合物。
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.046 秒)
